Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Blood (2024) 144 (Supplement 1): 892.

https://doi.org/10.1182/blood-2024-204700

Published: 2024

Journal Articles

Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy

Anthea Gibbons, Nirija Ranjit Anderson, Lipi Chakravorty, Fiona Kwok, Hasib Sidiqi, Simon Gibbs, Dariusz Korczyk, Emad Uddin Abro, Peter Mollee

Blood (2023) 142 (Supplement 1): 2030.

https://doi.org/10.1182/blood-2023-179219

Published: 2023

Journal Articles

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

Anitria Cotton, Ryan Collinson, Lynne Wilson, Zi Yun Ng, Hun S Chuah, Michael F. Leahy, Rebecca Howman, Carolyn Grove, Hasib Sidiqi, Malcolm Webb, Darren Boey, Olivia Ruhen, Michael Phillips, Matthew Linden, Kathy Fuller, Wendy N. Erber, Ronald Hoffman, John D. Crispino, Belinda Guo

Blood (2023) 142 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2023-182140

Published: 2023

Journal Articles

“Double Hit” Myeloma: Detection By FISH and Flow Cytometry in Circulating Myeloma Plasma Cells

Wendy N. Erber, Thomas Mincherton, Stephanie Lam, Henry Hui, Hun Sheng Chuah, Hasib Sidiqi, Kathy Fuller

Blood (2023) 142 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2023-180361

Published: 2023

Journal Articles

Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen

Lipi Chakravorty, Anthea Gibbons, Nirija Anderson, Fiona Kwok, Dariusz Korczyk, Emad Uddin Abro, Stephanie Lam, Simon Gibbs, Peter Mollee, M Hasib Sidiqi

Blood (2023) 142 (Supplement 1): 4781.

https://doi.org/10.1182/blood-2023-186335

Published: 2023

Journal Articles

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Blood (2023) 142 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2023-185169

Published: 2023

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Costas K. Yannakou, Nicholas Murphy, Rosemary Anne Harrup, Craig Wallington-Gates, Magdalena Sobieraj-Teague, M Hasib Sidiqi, Anish Puliyayil, Wojt Janowski, John Reynolds, Andrew Spencer, Hang Quach

Blood (2023) 142 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2023-185944

Published: 2023

Journal Articles

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Blood (2023) 142 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2023-178778

Published: 2023

Journal Articles

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Murielle Roussel, Peter Mollee, Antoine Huart, Hasib Sidiqi, Noemi Horvath, Lionel Karlin, Caroline Jacquet, Pierre Morel, Cecile Leyronnas, Sebastien Bender, Frank Bridoux, Arnaud Jaccard, Simon D. Gibbs

Blood (2022) 140 (Supplement 1): 12618–12620.

https://doi.org/10.1182/blood-2022-166337

Published: 2022

Journal Articles

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Nicholas E. Murphy, Hasib Sidiqi, Craig Thomas Wallington-Beddoe, Anish Puliyayil, Costas K. Yannakou, Wojt Janowski, Flora Yuen, Andrew Spencer, Hang Quach

Blood (2021) 138 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2021-151871

Published: 2021

Journal Articles

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Portia Smallbone, MBBS, Stephanie Clugston, MBBS (Hons), Rebecca De Kraa, BSc, Duncan Purtill, MBBS,FRCPA,FRACP, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-141783

Published: 2020

Journal Articles

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Stephanie Clugston, MBBS (Hons), Portia Smallbone, MBBS, Duncan Purtill, MBBS,FRCPA,FRACP, Dustin Hall, MBBS,FRCPA,FRACP, Rebecca De Kraa, BSc, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141784

Published: 2020

Journal Articles

Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

Abdullah S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Harsh Parmar, MD, Alissa Visram, MD, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Prashant Kapoor, MD, Robert Wolf, PharmD, RPh, Angela Dispenzieri, MD, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-143076

Published: 2020

Journal Articles

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Georgia J McCaughan, MBBS, Steven Tran, BEng MBiomedE, Simon Durrant, MBBS FRCP FRCPath, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, James Morton, MBBS BSci (MD FRACP FRCPA GAICD, Noemi Horvath, MB ChB FRACP FRCPA, Andrew Spencer, Ian H. Kerridge, FRACP FRCPA MPhil BA, Jeremy An Ke Er, MBBS, Luani Barge, MChD, BSc, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA, Robin J Filshie, MBChB, PhD FRACP, FRCPA, Emily Choong, BSc MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS FRACP, Anthony K Mills, MBBS FRACP FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, John Moore, MB.BS, MD FRACP, FRCPA, Mark Hertzberg, MBBS PhDFRACP FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), M Hasib Sidiqi, MBBS, John Bashford, BSc MBBS FRACP FRCPA, David Routledge, BSc (Hons) MBChB MSc PGCert MRCP FRCPath UK RACP, Kerry Taylor, MBBS(Hons) FRACP FRCPA, Cindy H. Lee, MBBS FRACP FRCPA, Anna Kalff, MBBS (Hons) FRACP FRCPA, Wei Xia, MBBS PhD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138991

Published: 2020

Journal Articles

Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis

Abdullah S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Harsh Parmar, MD, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Francis K. Buadi, MB, CHB, David Dingli, MD PhD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Prashant Kapoor, MD, Robert Wolf, PharmD, RPh, Angela Dispenzieri, MD, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-143125

Published: 2020

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Kalyan Nadiminti, M Hasib Sidiqi, MBBS, Kapil Meleveedu, MDMBBS, Hassan B. Alkhateeb, MD, Aref Al-Kali, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Shaji K. Kumar, MD, Mrinal M Patnaik, MDMBBS, Morie A. Gertz, MD, Dong Chen, MD PhD, Mithun Vinod Shah, MD PhD

Blood (2019) 134 (Supplement_1): 4560.

https://doi.org/10.1182/blood-2019-123065

Published: 2019

Journal Articles

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Abdullah S. Al Saleh, MBBS, M Hasib Sidiqi, MBBS, Morie A. Gertz, MD, Eli Muchtar, MD, Martha Q. Lacy, MD, Rahma M Warsame, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, William J Hogan, MB, BCh, Suzanne R. Hayman, MD, Prashant Kapoor, MD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, David Dingli, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 4505.

https://doi.org/10.1182/blood-2019-131380

Published: 2019

Journal Articles

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Adeela Mushtaq, MD, Hamza Hassan, MD MBBS, Razwana Khanam, MD, Ahmad Iftikhar, MD, Midhat Lakhani, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Maaz Ahmed Yusufi, MD, Seemal Iftikhar, MD, Aneeqa A Zafar, MD, Irbaz Riaz, MDMMSc, M Hasib Sidiqi, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5556.

https://doi.org/10.1182/blood-2019-125148

Published: 2019

Journal Articles

Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis

Abdullah S. Al Saleh, MBBS, M Hasib Sidiqi, MBBS, Eli Muchtar, MD, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, Rahma M Warsame, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Nelson Leung, MD, Wilson I Gonsalves, MD, Taxiarchis Kourelis, MD, Prashant Kapoor, MD, Ronald S. Go, MD, Robert A. Kyle, MD, S. Vincent Rajkumar, MD, Morie A Gertz, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 5532.

https://doi.org/10.1182/blood-2019-131171

Published: 2019

NARROW

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy

Upregulation of Platelet Transcripts As Biomarkers of Fibrotic Progression in Myeloproliferative Neoplasms

“Double Hit” Myeloma: Detection By FISH and Flow Cytometry in Circulating Myeloma Plasma Cells

Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Primary Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma

Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only